Clinical Trial Detail

NCT ID NCT01975701
Title A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

glioblastoma multiforme

Therapies

Infigratinib

Age Groups: adult

Additional content available in CKB BOOST